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Bacteria comprise the earliest form of independent life on this planet. Bacterial
development has included co-operative symbiosis with plants (e.g., Leguminosae family
and nitrogen fixing bacteria in soil) and animals (e.g., the gut microbiome). A fusion event
of two prokaryotes evolutionarily gave rise to the eukaryote cell in which mitochondria may
be envisaged as a genetically functional mosaic, a relic from one of the prokaryote cells.
The discovery of bacterial inhibitors such chloramphenicol and others has been exploited
to highlight mitochondria as arising from a bacterial progenitor. As such the evolution of
human life has been complexly connected to bacterial activity. This is embodied, by the
appearance of mitochondria in eukaryotes (alphaproteobacteria contribution), a significant
endosymbiotic evolutionary event. During the twentieth century there was an increasing
dependency on anti-microbials as mainline therapy against bacterial infections. It is only
comparatively recently that the essential roles played by the gastrointestinal tract (GIT)
microbiome in animal health and development has been recognized as opposed to the
GIT microbiome being a toxic collection of micro-organisms. It is now well-documented
that the GIT microbiome is comprised of a complex cohort of commensal and potentially
pathogenic bacteria. Microbial interactions in the GIT provide the necessary cues for
the development of regulated signals [in part by reactive oxygen species (ROS)] that
promote immunological tolerance, metabolic regulation and stability, and other factors,
which may then help control local and extra-intestinal end organ (e.g., kidneys) physiology.
Pharmacobiotics, the administration of live probiotic cultures is an exciting growth area of
potential therapeutics, developing together with an increased scientific understanding of
GIT microbiome symbiosis in health and disease. Hence probiotic bacteria may provide a
therapeutic connect with the GIT microbiome that can rescuemitochondrial dysfunction by
linking a biologically plausible cellular signaling program (ROS reliant) between the human
host and its microbiome cohort for a continued co-operative symbiosis that maintains
homeostasis favorable to both.
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INTRODUCTION
Bacteria have always conducted and orchestrated life on earth.
They do so, by way of a large body of versatile metabolic activities,
carrying out numerous biochemical actions such as maintaining
the basic carbon, sulfur and nitrogen cycles. As such, bacteria can
currently be found to inhabit multiple domains namely, terres-
trial, aquatic, plant, and animal systems. The human microbiome
includes not only the GIT but also all other mucosal surfaces and
the skin, each with its own specific microbiome. The evolution
of a primordial prokaryote fusion that led to the development
of the eukaryote cell (i.e., acquisition of mitochondria) has been
hypothesized as arising from an oxygen consuming bacterial
ancestor (Dolan and Margulis, 2007; Shih and Matzke, 2013) by
endosymbiosis; an event that highlights a significant evolution-
ary step, that is obligatory for the continued symbiotic existence
between bacteria and plants and animals, that is vital for life and
survival on this planet.
It is reported that the GIT of man harbors the densest and
perhaps the most diverse concentration of bacteria known with
an average of 1012−14 bacterial cells (predominantly in the large
bowel) per wet weight of luminal content (Booijink et al., 2010).
However, recent reports suggest that the skin microbiome may be
just as dense and complex (Grice and Segre, 2011). Overall, there
has been estimated to be 10 times more bacterial cells living on
and within humans than there are human cells (Bäckhed et al.,
2005).
The general scientific consensus has been that the fetus in utero
was essentially micro-organism free indicating that post-natal
infections were primordial formucosal tissue andmetabolic func-
tionality development and maturation. However, a recent study
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has cast significant doubt on this notion, reporting a unique pla-
cental microbiome niche that was composed of non-pathogenic
commensal bacteria similar in composition to the human oral
microbiome (Aagaard et al., 2014). Hence in utero contact with
placental commensal microbes followed by post birth amplifi-
cation of bacterial cues that ensue, provide pro-inflammatory
signals that induce mucosal tissue maturation. This complex
activity is believed to shape immune tissue development and
metabolic up-regulation that eventually provide the new born
with a scaffolding of immunological tolerance and metabolic
stability (Tremaroli and Bäckhed, 2012). Hence a multifaceted
symbiosis is therefore established between human, bacterial, and
archaeal species.
MITOCHONDRIA AND BACTERIA
There is nothing more central to physiological processes and bio-
logical function than its energy supply systems, the generation
of exportable energy (ATP) is largely the role of the mitochon-
drial oxidative phosphorylation system (glycolysis being the only
other significant source of net ATP synthesis) (Alberts et al.,
2002). Therefore, the major role of mitochondria is cellular aer-
obic energy generation, and as such mitochondria have played a
key role in the evolution of complex cellular systems/animals. The
mitochondrial genome strongly supports the incorporation of an
ancestral pre-eukaryote (a bacterial endosymbiont) (Gray et al.,
1999), positing that, mitochondria arose from an endosymbi-
otic event through the contribution of an alpha-proteobacterium
(Burger and Lang, 2003). A key discovery that supports an
alpha-proteobacterium contribution to mitochondrial evolution
is extant in Rickettsia an alpha-proteobacteria that multiplies only
in eukaryotic cells.
In their studies on the origin and evolution of mitochondria
Andersson et al. (1998) in effect reported that ATP production in
Rickettsiawas the same as that found in mitochondria. Andersson
et al. (1998) demonstrated that Rickettsia prowazekii (an obli-
gate intracellular parasite) and mitochondria have a complete set
of genes and a similar collection of proteins that are involved
in numerous cellular processes associated with energy produc-
tion. These include, ATP production and transport, including
genes encoding components of the TCA cycle, the respiratory
chain complexes, the ATP-synthase complexes and the ATP/ADP
translocases. Moreover, they showed that there were also some
similarities in the gene orders of some of the functional clus-
ters. Andersson et al. (1998) concluded that phylogenetic anal-
yses signposted that R. prowazekii was closely related to the
mitochondrion organelle than was any other microbe studied.
Additional bacterial genome based research (Abhishek et al.,
2011) has demonstrated matches of mitochondrial genes to
those of members of the Anaplasmataceae, and Rhodospirillaceae
families, showing that significant bacterial genome chimaerism
had occurred en route to the formation of mitochondria in
eukaryotic cells.
The mitochondrial electron transport system also produces
reactive oxygen species (ROS), which through the agency of
hydrogen peroxide notably regulate the redox state within cells
that subsequently regulate intracellular metabolism (Linnane
et al., 2007). ROS redox signaling has also been reported for
the gut microbiota, giving rise to the concept that a conserved
mode of cellular communication is present in bacteria (Neish,
2013) that could be perceived to mirror that, which is articu-
lated by mitochondria in eukaryotic cells. Recently it has been
further hypothesized (Vitetta et al., 2013a) that dysbiosis (a gut
barrier associated abnormality that increases permeability) of the
gastrointestinal tract may contribute to disease processes and
their progression. Further, that pharmaceutical drug administra-
tion (e.g., analgesic medications) has been linked to gut dysbiosis
(Scarpignato and Hunt, 2010).
Early electron microcopy and subcellular organelle marker
enzyme studies with rat small intestine samples following the
administration of a non-steroidal anti-inflammatory (NSAID)
agents (i.e., indomethacin) suggested that drugs such as NSAID’s
induced changes in mitochondrial energy production. Hence it
was reasoned that NSAID’s thereby uncoupled mitochondrial
oxidative phosphorylation by inducing an injurious insult on
the organelle (Somasundaram et al., 1997). Animal studies have
demonstrated mitochondrial morphological changes with the
administration of pharmaceutical products such as NSAIDs (Leite
et al., 2004).
Furthermore, maintaining the GIT ecosystem in a balanced
state is a critical requisite for the control of pathogenic bacteria
and the associated toxin load produced in the small and large
bowel. Recent clinical trial reports with osteoarthritis patients
administered analgesic medications (Coulson et al., 2012, 2013)
continue to support the notion (Bengmark, 2013) that pharma-
cotherapy can induce adverse metabolic conditions on the gut
microbial unit. This activity in turn serving to disrupt GIT home-
ostasis and contributing toward a dysbiotic burden that increases
the risk of infective sequelae that can disrupt eukaryotic signaling
and functionality.
COMMENSAL BACTERIA AND CONSERVED CELLULAR
SIGNALING
The GIT mucosa is one of the most metabolically active tis-
sues and attendant basic research has significantly redefined the
exchanges that ensue between gut-dwelling bacteria and their
vertebrate hosts. It is now very much recognized that the micro-
bial active cohort and its mammalian host have shared not only
important but critical co-evolutionary metabolic interactions
that span millennia, this then serving to imprint an important
endosymbiotic evolutionary event for human survival on this
planet. Experiments with gnotobiotic animals (e.g., mice living
in germ-free environments) has demonstrated that while the ver-
tebrate host provides the framework genes for proper immune
system functionality and therefore antigen tolerance (Falk et al.,
1998), the commensal bacterial cohort provides the necessary
signals that completes the process of mucosal tissue maturation.
The intestinal mucosal surface is a complex and interactional
environment, which is continuously exposed to a range of com-
mensal microorganisms. The human-microbial GIT boundary
is an ecosystem that shares in a variety of important roles in
human health and disease (Dominguez-Bello et al., 2010; Pepper
and Rosenfeld, 2012). Inflammatory diseases of the GIT are
often reported to severely disrupt the gut epithelial tight junc-
tion barrier (Qin et al., 2012; Koboziev et al., 2013) with oxidative
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stress purported to drive metabolic abnormalities in the gut
that contribute to chronic disease development (Zhu and Li,
2012). Probiotics can affect a range of GIT physiological func-
tions, including control over immune responses, epithelial barrier
function and cellular proliferation (Vitetta et al., 2013). Recent
investigations have demonstrated that some genera of humanGIT
bacteria can induce a rapid increase of ROS, eliciting a phys-
iological response through the activation of epithelial NADPH
oxidase-1 (Nox1) (Bermudez-Brito et al., 2012; Neish, 2013). In
addition, reports site in vitro experiments with epithelial cells
that, when co-cultured with specific probiotic bacteria, show an
increased and rapid oxidation reaction of soluble redox sinks,
namely glutathione and thioredoxin (Bermudez-Brito et al., 2012;
Neish, 2013) that indicate the presence of a regulated process. This
effect was demonstrated as an increase in the oxido-reductase
reaction of transcriptional factor activations such as nuclear fac-
tor kappa B (NFκB), NrF2 and the antioxidant response element,
reflecting a cellular response to increased ROS production that
is regulated (Bermudez-Brito et al., 2012; Neish, 2013). This
effect must be decisive in order to elicit a restrained anti-infective
response with a minimal chance of pro-inflammatory damage
to the tissue. These reactions hence, define potent regulatory
effects on host physiological functions that include intracellular
signaling that is conserved and shared that may further define an
endosymbiosis evolutionary event.
The reported mechanisms of action of probiotics are similarly
aligned acting to enhance the epithelial barrier, increased bacterial
adhesion to the intestinal mucosa, with an attendant inhibition
of pathogen adhesion to the competitive exclusion of pathogenic
microorganisms (Lee, 2008; Lin et al., 2009; Bermudez-Brito
et al., 2012; Neish, 2013). Furthermore, probiotic strains have
also been reported to generate a range of anti-microbial sub-
stances and to positively affect and modulate immune system
function. Lee (2008) has reported that the enteric commensal bac-
teria by rapidly generating ROS negotiate an acceptance by the
GIT epithelia. Different strains of commensal bacteria can elicit
markedly different levels of ROS from contacted cells. Lactobacilli
are especially potent inducers of ROS generation in cultured
cells and in vivo, though all bacteria tested have some ability to
alter the intracellular oxido-reductase environment (Lin et al.,
2009). Yan et al. (2007) has reported that there are soluble fac-
tors that are produced by strains of lactobacilli that are capable of
mediating beneficial effects in in vivo inflammatory models. This
result expands our understanding of the microbiome’s activity
that there are ROS-stimulating bacteria that possess effective spe-
cific membrane components and or secreted factors that activate
cellular ROS production to maintain homeostasis.
It has been reported that redox signaling by microbial ROS
formation is in response to microbial signals via formyl pep-
tide receptors and the gut epithelial NADPH oxidase 1 (Nox1)
(Neish, 2013). As we have previously documented (Linnane
et al., 2007) ROS generated by Nox enzymes have been shown
to function as essential second messengers in multiple signal
transduction metabolic pathways through the rapid and tran-
sient oxidative inactivation of a distinct class of sensor proteins
bearing oxidant-sensitive thiol groups. These redox sensitive pro-
teins include tyrosine phosphatases that attend as regulators
of the MAP kinase pathways, focal adhesion kinase (Linnane
et al., 2007; Neish, 2013). These reports focus our understand-
ing on the importance of second messenger functionality for
the maintenance of homeostasis and brings into serious ques-
tion the annulment of ROS by antioxidant supplements for the
amelioration of chronic diseases. The established importance
of recent investigations regarding probiotic/microbial-elicited
ROS teaches that stimulated cellular proliferation and motil-
ity is strictly controlled and is a regulated signaling process for
proper innate immunity and gut barrier functionality (Collier-
Hyams et al., 2005; Lin et al., 2009). The observations that the
vertebrate epithelia of the intestinal tract, supports a tolera-
ble low-level inflammatory response toward the GIT microflora,
can be viewed as an adaptive activity that maintains home-
ostasis (Neish et al., 2000). This adaptive activity is an impor-
tant link to an endosymbiotic event that connects eukaryotic
cell function to bacteria via a conserved mode of communica-
tion that is via the upstream elaboration of ROS. Consider the
following.
Aconitase is an ancient enzyme important for the Krebs cycle
and is essential formitochondrial DNAmaintenance independent
of its catalytic activity. An ancestral endosymbiotic event from
bacteria that possessed and transmitted genes coding for aconitase
may be the link that partly rationalizes the acquisition of mito-
chondria (mitochondrial genes) by a pre-eukaryotic ancestor. A
group of bacterial endosymbionts may have added to the evo-
lutionary step that has led to the development of mitochondria.
Baughn and Malamy (2002) have suggested that a consortium of
endosymbionts from the Cytophaga-Flavobacterium-Bacteroides
phylum (of which Bacteroides fragilis is a member) may have
contributed the aconitase gene to the nucleus of an ancestral
eukaryotic cell. These endosymbionts providing a functional
duality, that is control of homeostasis for growth and pro-
tection from the deleterious effects of an oxygen rich atmo-
sphere that is analogous to the deleterious effects of oxidative
stress.
Recently, Bota et al. (2002, 2005) have reported that mito-
chondrial aconitase is preferentially oxidatively-modified and
inactivated, and that the ATP activation of the mitochondrial
Lon protease specifically acts to degrade the oxidized inactivated
aconitase enzyme. The authors interpret their results as demon-
strating the toxicity of ROS a concept indirectly supported by
Baughn and Malamy (2002). In contrast we believe that the
Bota et al. (2002, 2005) conclusion is in error (Linnane et al.,
2007); rather their results demonstrate how tightly-regulated is
the formation of ROS and its directed activity in regulating the
metabolome of the cell. The controlled specific degradation of
aconitase (among the hundreds of mitochondrial proteins) to
regulate the Krebs cycle’s activity is an excellent example of the
regulatory role that ROS play in the modulation or control of
the metabolome, and that ROS do not randomly contribute to the
damage or degradation of cellular metabolic processes. Rather,
that an ancient endosymbiotic event that gave rise to mitochon-
dria also evolved regulated ROS signaling pathways that are widely
distributed in diverse environments from soils to commensal
and probiotic bacteria found in the human gastrointestinal tract
(Neish, 2013).
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PROBIOTICS AND THE PRESERVATION OF GIT TOLERANCE
The mucosal surfaces and skin of vertebrates especially
humans have been reported to comprise specific, complex and
diverse microbial communities with distinct localized functions
(Dominguez-Bello et al., 2010). The idea that live microbial cul-
tures could enhance health and or prevent disease began to take
shape in the early part of the twentieth century, whenMetchnikoff
(Kaufmann, 2008) postulated that the administration of lactic
acid bacteria could significantly attenuate the growth and level of
pathogenic bacteria in the GIT.
Gut dysbiosis an impaired GIT mucosal barrier functional-
ity has been associated with numerous adverse health concerns
such as the accumulation of endotoxins, the translocation of
bacteria-derived lipopolysaccharides, and hyperactivation of the
immune system. The host-microbiota through a series of com-
plex cooperative tasks (e.g., mucus production, immune system
regulation) pursues the maintenance of homeostasis. Although
the clinical evidence for the benefits of probiotics is equivo-
cal, the clinical data indicate that probiotics provide both a
prophylactic and therapeutic benefit by regulating cell-signaling
pathways and cytokine production. We have previously reviewed
the published human studies of probiotics and prebiotics (a
nutritional supplement favoring the growth and increasing the
lifespan of probiotic bacteria) and their effects on several clin-
ical scenarios (Vitetta and Sali, 2008; Vitetta et al., 2013). The
probiotic strains that have been reported as clinically useful
include, Lactobacillus rhamnosus GG, various other Lactobacilli
and Bifidobacteria strains and the yeast Saccharomyces boulardii
(Hickson, 2011). The various species of probiotics that have been
clinically investigated differ from studies with single strains (e.g.,
Saccharomyces boulardii, Lactobacillus rhamnosus GG, Bacillus
clausii, Bifidobacterium longum, Clostridium butyricum miyairir,
Lactobacillus acidophilus, Enterococcus faecium SF68), to studies
with mixtures of two or more species of probiotics, or to a syn-
biotic [probiotic(s) combined with a prebiotic constituent (e.g.,
inulin)] (Hickson, 2011).
As an example a recent meta-analysis reported the adminis-
tration of probiotics for the prevention of Clostridium Difficile
Associated Diarrhea (CDAD) (Johnston et al., 2012). The
reported efficacy was for L. rhamnosus GG (dose: 109 − 1010
CFU/day); L. acidophilus (dose: 109 − 1010 CFU/day); S. boulardii
lyophilized (dose: 109 CFU/day); L. plantarum (dose: 109
CFU/day); L. acidophilus and L. casei (dose: 109 CFU/day) and
multi-strain probiotic (dose: 109 CFU/day). The duration of
follow-up varied from 2 to 12 weeks, and the risk of developing
CDAD was 0–24%. Hence the meta-analysis/systematic review
reported that 20 randomized trials testing the effect of probiotics
in patients receiving antibiotics showed a large relative risk reduc-
tion in the incidence of CDAD of 0.34 (CI, 0.24–0.49) (Johnston
et al., 2012). This has provoked further interest on the therapeutic
potential of the human GIT microbiome and probiotic admin-
istration. The beneficial effects occur, it would seem when the
GIT environment meets a multi-strain probiotic-enhanced GIT
commensal environment throughout the digestive tract.
CONCLUSION
Symbiosis between the human host and its bacterial cohort pro-
vide an interaction between two different organisms living in
close physical proximity that typically is advantageous to both.
The genomic pool provided by the human microbiota together
with the eukaryotic human nuclear genome harbor more than
nine million specific genes that control a multitude of metabolic
functions (Zoetendal et al., 2008). The GIT microbiome as a
biosensor for the production of numerous important metabo-
lites remains the most studied human site. As such and very likely
it will provide future novel therapeutic molecular discoveries.
Hence as the scientific understanding of microbial communities
progresses with the important elucidation of beneficial microbial
subspecies as opposed to pathogenic microbial subspecies (Vitetta
and Gobe, 2013), a novel therapeutic intervention that is microbe
directed and site-specific may be possible. Therefore, mechanis-
tically probiotic bacteria may rescue mitochondrial dysfunction
by linking a biologically plausible cellular signaling program
(ROS dependent) between the human host and its microbiome
cohort for a continued co-operative symbiosis that maintains
homeostasis favorable to both.
As a final thought, the RNA molecule is a primordial
molecular entity of life. The emerging evidence suggests that
there are more genes encoding regulatory RNAs than those
encoding proteins in the human genome (Morris and Mattick,
2014). Therefore, in the near future the role of RNAs in
eukaryote cell/mitochondria evolution will need to be seriously
considered.
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